PWRM%20is%20now%20available%20for%20$0.033%20cents%20a%20share.%20Since%20the%20beginning%20of%20June%202010%20PWRM%20has%20been%20trading%20in%20a%20channel.%20Pay%20attention%20for%20a%20possible%20breakout.%20PWRM%20deserves%20to%20be%20watched%20very%20closely!%20A%20breakout%20could%20be%20an%20indicator%20of%20possible%20momentum.PWRM%20pursues%20an%20aggressive%20intellectual%20property%20strategy%20to%20protect...){kind=link}
Pwrm, Ilmn, & Cah: Sequenom Rises As Ladenburg Says Buy, Jefferies Starts At Hold
POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)
PWRM is now available for $0.033 cents a share. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:
Processes - The manner in which the discoveries are made and tests developed
Discoveries - Protein disease footprints,
Products - Early detection tests, Biomarkers, and Drug Targets
The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance:
The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below:
Two of Power3 Medical Areas of Research
Breast Cancer
Power3s early indication breast cancer NAF protein footprint test
More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer
NAF footprints for individualized therapy
Neurodegenerative Diseases - ALS (Lou Gehrigs Disease), Alzheimers Disease, Parkinsons Disease, Other Neurological Disorders
Power3s blood serum test for distinguishing between the neurodegenerative diseases
Blood serum biomarkers and drug targets for neurodegenerative disease
Resistance to Chemotherapy
Power3s test for prediction of response to drug therapy in cancer
Biomarkers and drug targets for treatment and monitoring of drug resistance
Continue your research at www.power3medical.com
___________________________________
Recent News: Sequenom Rises as Ladenburg Says Buy, Jefferies Starts at Hold
Illumina, Inc. (NASDAQ:ILMN) reported the appointment of B. Melina Cimler, Ph.D., as Vice President, Quality and Regulatory Affairs, reporting to Christian Henry, Senior Vice President, Chief Financial Officer and General Manager, Life Sciences. Dr. Cimler will lead Illuminas quality and regulatory organizations to support the development, manufacture and distribution of products serving the research, consumer and molecular diagnostic markets.
Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include HiSeq 2000, an instrument for high-throughput (up to 200 Gb per run and up to 25 GB per day) sequencing using sequencing-by-synthesis (SBS) technology; Genome Analyzer IIx, an instrument for medium to high-throughput (up to 95 Gb per run) sequencing using SBS technology; Genome Analyzer IIe, an instrument for low to medium throughput (up to 40 Gb per run) sequencing using SBS technology; iScan System, a high-resolution imaging instrument to scan BeadArray based assays; and BeadXpress Reader, a low- to mid-multiplex, high-throughput instrument for readout of assays.
For More Info Visit: http://www.illumina.com
___________________________________
Recent News: Cardinal Health deal for Healthcare Solutions OKd
Cardinal Health (NYSE:CAH) announced plans to expand its presence in specialty pharmaceutical services with a definitive agreement to purchase Healthcare Solutions Holding, LLC in an upfront $517 million all-cash transaction. The agreement also includes the opportunity for earn-out payments of up to $150 million over the next three years.
Healthcare Solutions Holding is the parent company of a number of subsidiaries including P4 Pathways and P4 Healthcare. These businesses serve key participants across the chain of specialty care including physicians, pharmaceutical companies and payors by providing essential tools, services and data to help improve the quality of patient outcomes and increase efficiency in the delivery of health care services. The acquisition will expand Cardinal Healths current capabilities and reach in specialty pharmaceuticals, a segment of the market which IMS Health forecasts will grow at twice the rate of traditional pharmaceuticals for the next five years and exceed $100 billion in sales by 2013.
CAH is a $96 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability.
For more information please visit www.cardinalhealth.com
*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
*******************************************
by: Blayne Sheffield Syracuse Motion Pro , How Buy Your Next Atv Luxury Real Popular Online Shopping Stores Deserted Buy The Best Land In Tennessee Why You Should Buy A Kindle Where To Buy Stun Guns Instant Approval Payday Advance - Get Quick Fix Solution To Your Daily Wants Buy Blenders Save Your Money By Shopping Online Cheers - How To Buy A Liquor Store Creatively! Finding Out More About How To Buy A Telescope Taxi Insurance Be Wise And Shop Around Do not buy Maqui SuperBerry or to be exact no need to buy in quantity Rent to Buy - Buy to Let Landlords